Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen and welcome to the Ventyx Biosciences First Quarter 2024 Earnings Conference Call.
Ventyx Biosciences Inc. (VTYX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deerfield Management James E. Flynn | 6,715,501 | $14,639,792 | +16% | 0.21% |
| 2. | Citadel Investment Group Ken Griffin | 4,455,010 | $9,711,922 | -23% | 0% |
| 3. | Farallon Capital Thomas Steyer | 3,170,000 | $6,910,600 | 0.03% | |
| 4. | Tang Capital Management Kevin C. Tang | 3,100,000 | $6,758,000 | 0.48% | |
| 5. | Octagon Capital Advisors Ting Jia | 2,391,114 | $5,212,629 | 0.81% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.00 | 625,000 | Other | 1,410,303 | 2021-10-25 | Filing | |
| $16.00 | 312,500 | Large Shareholder, Other | 3,997,269 | 2021-10-25 | Filing | |
| $16.00 | 312,500 | Large Shareholder, Director | 3,997,269 | 2021-10-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.40 | 1,651 | 284,999 | 2024-04-02 | Filing | ||
| $5.40 | 1,651 | 264,998 | 2024-04-02 | Filing | ||
| $5.40 | 4,312 | 1,578,250 | 2024-04-02 | Filing | ||
| $5.40 | 1,405 | 24,303 | 2024-04-02 | Filing | ||
| $2.12 | 17,628 | Officer | 262,118 | 2023-12-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,814,531 | $9,421,890 | 0% | |
| 2. | 3,741,925 | $9,242,554 | 0% | |
| 3. | 2,354,149 | $5,814,748 | 0% | |
| 4. | 1,915,026 | $4,730,113 | 0% | |
| 5. | 1,362,789 | $3,366,089 | 0% |
News See All
12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds.
25 Biggest Stocks with Negative Beta
Stock markets were in see-saw mode before the Fed’s September decision on rate hikes.
Long-Term Returns of Dan Loeb's 5 Activist Targets
The investment came amid Loeb’s confidence about SentinelOne, Inc. (NYSE:S)’s growth potential and ability to disrupt the cyber security industry.
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences Second Quarter 2023 Earnings Conference Call.
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences First Quarter 2023 Earnings Conference Call.
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q4 2022 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences Fourth Quarter and Full Year 2022 Earnings Conference Call.
10 Best-Performing Non-Energy Stocks of 2022
On Friday, September 16, Wall Street concluded another one of its abysmal weeks in months, as investors reacted to a weak earnings indication from FedEx regarding the global economy.
Thomas Steyer's Farallon Capital is Buying These 10 Stocks
In this article, we discuss 10 stocks that Thomas Steyer’s Farallon Capital is buying.
10 Little-Known Stocks Billionaire Dan Loeb is Buying
Dan Loeb is an American activist investor who founded the New York-based hedge fund, Third Point, in 1995.
Billionaire Hedge Funds
